Oxiplex/AP® is now indicated for use as an adjunct to intrauterine or peritoneal surgery for reducing the incidence, extent, and severity of postoperative adhesions.

**EXCEPTIONAL CLINICAL RESULTS**

Fuchs et al. used Oxiplex/AP following hysteroscopic surgery in a randomized study of 52 women.¹

- Follow up at 20 months showed that Oxiplex/AP treated patients had fewer moderate to severe intra-uterine adhesions (4% vs. 16%) compared to control.
- Patients treated with Oxiplex/AP had an improved fertility rate (27% vs 14%) compared to controls.

Di Spiezio Sardo et al used Oxiplex/AP following hysteroscopic metroplasty to expand dysmorphic uteri in a prospective, observational study in 30 infertile women.²

- Oxiplex/AP gel was applied into the uterine cavity at the completion of the procedure through the inflow channel of the hysteroscope.
- At the mean follow-up of 15 months, clinical pregnancy rate was 57% and term delivery rate was 65%.
- Low incidence of post surgical synechiae attributed to the use of Oxiplex/AP gel.

Di Spiezio Sardo et al used Oxiplex/AP following hysteroscopic surgery in a randomized study of 110 patients.³

- Follow up at one month showed that Oxiplex/AP treated patients had fewer ‘de novo’ adhesions (6% vs 22%) compared to control.
- Patients treated with Oxiplex/AP also demonstrated improvement in the degree of patency of the internal uterine ostium.

**REFERENCES**


*CE Mark Certificate, 2010797CE01, dated 1 May 2017 on file. Approval in non-EU countries may be required prior to import/distribution.